Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.5
2.7
Journals
Applied Sciences
Special Issues
New Research in Molecular Cancer Biology
applsci-logo
Submit to Applied Sciences Review for Applied Sciences Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Research in Molecular Cancer Biology

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: closed (10 June 2022) | Viewed by 1986

Special Issue Editors

Prof. Dr. Zofia Mazerska

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, 80-233 Gdańsk, Poland
Interests: metabolic transformations of antitumor agents, general approach and the selected pathways; enzyme families involved in metabolism of anticancer therapeutics: P450s, FMOs, UGTs, SULTs, AOXs, XORs, MAOs, ALDHs, (liver and cytosolic enzymes); the relevance of metabolic transformations to drug resistance and to the activation mechanism in cancer treatments
Dr. Magdalena Niemira

E-Mail Website
Guest Editor
Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland
Interests: genomics; transcriptomics; biomarkers; translational research; next-generation sequencing; precision therapy
Dr. Anna Skwarska

E-Mail Website
Guest Editor
Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
Interests: cancer therapy; apoptosis; synthetic lethality; BH3-mimetic drugs

Special Issue Information

Dear Colleagues,

Cancer is not defined as a single disease, but a heterogeneous group of diseases, characterized by the accumulation of mutations in the genome of cells, to the point where these mutations affect the various functions at the molecular, cellular, tissue, and systemic levels. Development of cancer  requires several molecular alterations at multiple levels including genome, epigenome, transcriptome, proteome, and metabolome. Our increasing understanding of the molecular processes governing cell growth and differentiation positions molecular biology in the center of moder oncology research as it offers possibilities for discovery of new diagnostic markers and therapeutic targets. This Special Issue aims to present original research and review articles on molecular and cellular cancer biology related to the development, progression and therapy of cancer. It focuses on innovative discoveries, approaches, and technical development in molecular cancer research. We would also particularly encourage submissions that use omics studies as a means of better understanding of the underlying molecular mechanism of cancer and the opportunity for novel anti-cancer therapies.

Prof. Dr. Zofia Mazerska
Dr. Magdalena Niemira
Dr. Anna Skwarska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer molecular biology
  • regulation of signalling pathway
  • genomics
  • epigenetics
  • cancer biomarker
  • translation research
  • molecular biology
  • cancer progression
  • cancer metastasis
  • therapeutic targets

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2968 KiB  
Article
Circulating mRNA Expression of Astrocyte-Elevated Gene-1 Associated with Treatment Response and Survival in Non-Small Cell Lung Cancer Patients Treated with Pemetrexed
by You-Lung Chang, Yen-Fu Chen, Ying-Yin Chen, Shih-Chieh Chang, Cheng-Yu Chang, Yu-Feng Wei and Chung-Yu Chen
Appl. Sci. 2021, 11(23), 11334; https://doi.org/10.3390/app112311334 - 30 Nov 2021
Viewed by 1569
Abstract
Background: Astrocyte-elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis in non-small cell lung cancer (NSCLC). In this prospective study, we assessed the values of plasma AEG-1 mRNA expression by liquid biopsy associated with tumour response and survival in NSCLC patients treated [...] Read more.
Background: Astrocyte-elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis in non-small cell lung cancer (NSCLC). In this prospective study, we assessed the values of plasma AEG-1 mRNA expression by liquid biopsy associated with tumour response and survival in NSCLC patients treated with pemetrexed. Methods: Patients diagnosed with advanced NSCLC were enrolled to be treated with pemetrexed combined with platinum as first-line chemotherapy. All patients underwent blood sampling before any cancer treatment (C0) and at first response evaluation after two cycles (C2) of treatments. Response to chemotherapy and survival were assessed. Plasma mRNA was extracted from peripheral blood mononuclear cell (PBMC) and quantification of RNA was performed by real-time PCR. Results: A total of 50 patients with advanced NSCLC were included and 13 of 50 patients combined with bevacizumab. In patient groups of stable disease (SD) (n = 13) and progressive disease (PD) (n = 10), the plasma mRNA of AEG-1, thymidylate synthase (TS), and CK19 were elevated significantly at C2 compared to patients in treatment response group (PR, n = 27) (PR vs. SD or PD, AEG-1: 1.22 ± 0.80 vs. 4.51 ± 15.45, p = 0.043). NSCLC patients who had elevated AEG-1 (AEG-1 ≥ 2) after two cycles of chemotherapy had shorter PFS and OS (high AEG-1 vs. low AEG-1, median, PFS: 5.5 vs. 11.9 months, p = 0.021; OS: 25.9 vs. 40.8 months, p = 0.019, respectively). In a Cox regression analysis, increased plasma mRNA expression of AEG-1indicated poor prognosis in survival. Conclusions: Circulating mRNA concentration of AEG-1 could be a predictive and prognostic biomarker in NSCLC patients treated with pemetrexed. Increased expression of AEG-1 contributed to the chemoresistance and caused lung cancer progression. Full article
(This article belongs to the Special Issue New Research in Molecular Cancer Biology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop